Analysis of the National Institute of Neurological Disorders and Stroke Tissue Plasminogen Activator Studies Following European Cooperative Acute Stroke Study III Patient Selection Criteria

Journal of Stroke and Cerebrovascular Diseases

Volumn 19, Issue 4, 2010, Pages 290-293

  Hemmen, Thomas M ^a   Rapp, Karen S ^a   Emond, Jennifer A ^b   Raman, Rema ^b   Lyden, Patrick D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute stroke; stroke care; stroke management; thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RANKIN SCALE; SCORING SYSTEM; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; BRAIN ISCHEMIA; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; RISK; TIME; UNITED STATES;

ADOLESCENT; ADULT; AGED; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; ODDS RATIO; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 77953589787     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2009.06.001     Document Type: Article

References (13)

1. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European cooperative acute stroke study (ECASS). JAMA 274 (1995) 1017-1025
2. Hacke W., Kaste M., Fieschi C., et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II): Second European-Australasian acute stroke study investigators. Lancet 352 (1998) 1245-1251
3. Clark W.M., Wissman S., Albers G.W., et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: A randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 282 (1999) 2019-2026
4. Donnan G.A., Davis S.M., Chambers B.R., et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian streptokinase (ASK) trial study group. JAMA 276 (1996) 961-966
5. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet 346 (1995) 1509-1514
6. Hommel M., Boissel J.P., Cornu C., et al. Termination of trial of streptokinase in severe acute ischemic stroke: Mast study group. Lancet 345 (1995) 57
7. Hacke W., Furlan A.J., Al-Rawi Y., et al. Intravenous desmoteplase in patients with acute ischemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (dias-2): A prospective, randomized, double-blind, placebo-controlled study. Lancet Neurol 8 (2009) 141-150
8. Hacke W., Kaste M., Bluhmki E., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359 (2008) 1317-1329
9. The National Institute of Neurological Disorders and Stroke rt-Pa Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
10. Clark W.M., and Madden K.P. Keep the three hour tPa window: The lost study of ATLANTIS. J Stroke Cerebrovasc Dis 18 (2009) 78-79
11. Hosmer D.W., and Lemeshow S. Applied logistic regression (1989), John Wiley and Sons, New York
12. Engelter S.T., Bonati L.H., and Lyrer P.A. Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age-a systematic review across cohort studies. Age Ageing 35 (2006) 572-580
13. Demchuk A.M., Tanne D., Hill M.D., et al. Predictors of good outcome after intravenous tPa for acute ischemic stroke. Neurology 57 (2001) 474-480